Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Cabozantinib> ?p ?o }
- Cabozantinib abstract "Cabozantinib (INN) (development code name XL184; marketed under the trade name Cometriq) is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc. Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, hepatocellular and kidney cancers.Cabozantinib will be distributed in Europe by the French pharmaceutical company Ipsen after a collaboration was reached with Exelixis in March of 2016.".
- Cabozantinib atcPrefix "L01".
- Cabozantinib atcSuffix "XE26".
- Cabozantinib casNumber "849217-68-1".
- Cabozantinib chEBI "72317".
- Cabozantinib fdaUniiCode "1C39JW444G".
- Cabozantinib iupacName "N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide".
- Cabozantinib thumbnail Cabozantinib.svg?width=300.
- Cabozantinib wikiPageExternalLink Abstracts?&vmview=abst_detail_view&confID=65&abstractID=35249.
- Cabozantinib wikiPageExternalLink 270085-exelixis-looming-cancer-conference-a-favorable-swing-trade-opportunity.
- Cabozantinib wikiPageID "31813863".
- Cabozantinib wikiPageLength "9668".
- Cabozantinib wikiPageOutDegree "29".
- Cabozantinib wikiPageRevisionID "708152520".
- Cabozantinib wikiPageWikiLink Angiogenesis.
- Cabozantinib wikiPageWikiLink C-Met.
- Cabozantinib wikiPageWikiLink C-Met_inhibitors.
- Cabozantinib wikiPageWikiLink CYP3A4.
- Cabozantinib wikiPageWikiLink Category:Cyclopropanes.
- Cabozantinib wikiPageWikiLink Category:Fluoroarenes.
- Cabozantinib wikiPageWikiLink Category:Quinolines.
- Cabozantinib wikiPageWikiLink Category:Tyrosine_kinase_inhibitors.
- Cabozantinib wikiPageWikiLink Exelixis.
- Cabozantinib wikiPageWikiLink Food_and_Drug_Administration.
- Cabozantinib wikiPageWikiLink Foretinib.
- Cabozantinib wikiPageWikiLink Glioblastoma_multiforme.
- Cabozantinib wikiPageWikiLink International_nonproprietary_name.
- Cabozantinib wikiPageWikiLink Ipsen.
- Cabozantinib wikiPageWikiLink Kinase_insert_domain_receptor.
- Cabozantinib wikiPageWikiLink Medullary_thyroid_cancer.
- Cabozantinib wikiPageWikiLink National_Comprehensive_Cancer_Network.
- Cabozantinib wikiPageWikiLink New_drug_application.
- Cabozantinib wikiPageWikiLink Orphan_drug.
- Cabozantinib wikiPageWikiLink Phases_of_clinical_research.
- Cabozantinib wikiPageWikiLink Progression-free_survival.
- Cabozantinib wikiPageWikiLink Prostate_cancer.
- Cabozantinib wikiPageWikiLink Small_molecule.
- Cabozantinib wikiPageWikiLink Survival_rate.
- Cabozantinib wikiPageWikiLink Trade_name.
- Cabozantinib wikiPageWikiLink Tyrosine-kinase_inhibitor.
- Cabozantinib wikiPageWikiLink VEGF_receptors.
- Cabozantinib wikiPageWikiLinkText "Cabozantinib".
- Cabozantinib wikiPageWikiLinkText "cabozantinib".
- Cabozantinib atcPrefix "L01".
- Cabozantinib atcSuffix "XE26".
- Cabozantinib c "28".
- Cabozantinib casNumber "849217".
- Cabozantinib chebi "72317".
- Cabozantinib chembl "2105717".
- Cabozantinib chemspiderid "25948202".
- Cabozantinib eliminationHalfLife "198000.0".
- Cabozantinib excretion "Faeces , urine".
- Cabozantinib f "1".
- Cabozantinib h "24".
- Cabozantinib iupacName "N--N'-cyclopropane-1,1-dicarboxamide".
- Cabozantinib kegg "D10062".
- Cabozantinib legalUs "Rx-only".
- Cabozantinib licenceUs "Cabozantinib".
- Cabozantinib metabolism "Hepatic".
- Cabozantinib molecularWeight "501.51".
- Cabozantinib n "3".
- Cabozantinib o "5".
- Cabozantinib pregnancyUs "D".
- Cabozantinib proteinBound "≥99.7%".
- Cabozantinib routesOfAdministration "Oral".
- Cabozantinib smiles "O=CNC=CC=C3OC4=CC5=NC=C4".
- Cabozantinib stdinchi "1".
- Cabozantinib stdinchikey "ONIQOQHATWINJY-UHFFFAOYSA-N".
- Cabozantinib synonyms "XL184, BMS907351".
- Cabozantinib tradename "Cometriq".
- Cabozantinib unii "1".
- Cabozantinib wikiPageUsesTemplate Template:Drugbox.
- Cabozantinib wikiPageUsesTemplate Template:Ebicite.
- Cabozantinib wikiPageUsesTemplate Template:Extracellular_chemotherapeutic_agents.
- Cabozantinib wikiPageUsesTemplate Template:Reflist.
- Cabozantinib subject Category:Cyclopropanes.
- Cabozantinib subject Category:Fluoroarenes.
- Cabozantinib subject Category:Quinolines.
- Cabozantinib subject Category:Tyrosine_kinase_inhibitors.
- Cabozantinib hypernym Inhibitor.
- Cabozantinib type ChemicalSubstance.
- Cabozantinib type Drug.
- Cabozantinib type Drug.
- Cabozantinib type Heterocycle.
- Cabozantinib type Inhibitor.
- Cabozantinib type Organofluoride.
- Cabozantinib type Organohalide.
- Cabozantinib type Redirect.
- Cabozantinib type Organofluoride.
- Cabozantinib type Organohalide.
- Cabozantinib type ChemicalObject.
- Cabozantinib type Thing.
- Cabozantinib type Q8386.
- Cabozantinib comment "Cabozantinib (INN) (development code name XL184; marketed under the trade name Cometriq) is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc. Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer.".
- Cabozantinib label "Cabozantinib".
- Cabozantinib sameAs Q795057.
- Cabozantinib sameAs Cabozantinib.
- Cabozantinib sameAs Cabozantinib.
- Cabozantinib sameAs m.0gtvzpd.
- Cabozantinib sameAs Kabozantinib.